Alopecia areata is one of the conditions that patients find most alarming precisely because it appears suddenly and looks dramatic. A circular patch of hair loss — typically on the scalp, but sometimes on the beard, eyebrows, eyelashes, or body hair — appearing over days to weeks, with no obvious cause, in otherwise healthy skin. The skin within the patch is smooth and normal in appearance, not scarred or inflamed. The follicles are still present.
Understanding this last point is crucial: in alopecia areata, the hair follicle is not destroyed — it is arrested. The underlying mechanism is an autoimmune attack — the immune system mistakenly targets the immune-privileged follicle, allowing T-lymphocytes to attack the follicle bulb. The follicle stops producing hair but remains viable. This is why alopecia areata treatment delhi can produce full regrowth — and why regrowth can sometimes occur spontaneously in mild cases without treatment.
Key Takeaways
- Follicles Are Arrested, Not Destroyed: Treatment can reactivate viable follicles — early intervention produces the best regrowth outcomes.
- Intralesional Triamcinolone Is First-Line: Intralesional steroid injections directly into affected patches are the established first-line treatment for patchy disease.
- JAK Inhibitors Have Changed Severe Disease Management: New therapies including tofacitinib and baricitinib produce meaningful regrowth in alopecia totalis and alopecia universalis.
- Exclamation Mark Hairs Signal Active Disease: Their presence at a patch border means the patch is still expanding — treatment should begin promptly.
- The Condition Can Recur: The autoimmune predisposition persists — long-term management strategies reduce recurrence risk.
The Clinical Spectrum: From Patchy Loss to Complete Hair Absence
Alopecia areata ranges considerably in severity. The typical presentation is one or more oval or circular patches of hair loss on the scalp — the most common and most treatable form. The patches may be single or multiple, and can coalesce to form larger areas of loss.
Alopecia totalis — complete loss of all scalp hair — and alopecia universalis — complete loss of all hair on the scalp and body — represent the severe end of the spectrum. These forms are significantly harder to treat and have lower rates of full response, though newer JAK inhibitor therapy has changed the treatment landscape substantially.
Important diagnostic features include: the sharply defined patch with smooth normal skin within it; exclamation mark hairs at the patch border (short hairs that taper at the base — a specific finding in active alopecia areata); nail pitting alopecia (small regular pits in the fingernails, present in approximately 10–66% of patients); and the dermoscopic appearance of follicles at the patch edge. A dermatologist trained in trichoscopy can confirm the diagnosis clinically without biopsy in most cases.
The Autoimmune Mechanism: Why the Immune System Attacks the Follicle
Hair follicles normally maintain an immune-privileged state — they suppress local immune activity around themselves, preventing T-lymphocytes from recognising follicle components as foreign. In alopecia areata, this immune privilege is lost — T-lymphocytes penetrate the follicle bulb region, creating an inflammatory environment that disrupts the anagen phase of hair growth and causes the follicle to prematurely enter catagen and then telogen, with eventual hair shedding.
Genetic susceptibility is well-established — alopecia areata runs in families and is associated with several immune-regulatory genes. Stress, viral infections, and other autoimmune conditions (particularly thyroid disease, vitiligo, and atopic dermatitis) are associated, though causation is complex. This autoimmune mechanism determines the treatment approach: rather than stimulating hair growth directly, treatment works by suppressing or modulating the immune attack on the follicle — allowing the viable follicle to resume its normal growth cycle.
Treatment Approaches: What a Dermatologist Uses
Intralesional Triamcinolone: First-Line for Patchy Disease
Intralesional triamcinolone acetonide — corticosteroid injected directly into affected scalp patches — is the first-line, most well-established treatment for patchy alopecia areata. It delivers potent anti-inflammatory and immunosuppressive effect locally, suppressing the T-lymphocyte activity attacking the follicle and allowing it to resume growth.
Injections are administered at four to six weekly intervals using a diluted triamcinolone acetonide solution. Response is usually visible within six to eight weeks — fine, often initially white or colourless regrowth appearing within the treated area. The main risk is skin atrophy at the injection site if the concentration is too high or injections are placed too superficially — managed through careful dilution, correct depth, and appropriate session intervals. See our Intralesional Triamcinolone page.
Topical and Systemic Corticosteroids
For patients who cannot tolerate injections, or with larger areas of involvement, potent topical corticosteroids applied to the patches are a first-line alternative. They are less effective than intralesional injections for established patches but are useful for maintenance and for early or very active disease. Short courses of oral corticosteroids are sometimes used to arrest rapidly spreading disease — but long-term side effects preclude their use as ongoing maintenance therapy.
Topical Immunotherapy with DPCP
Topical immunotherapy DPCP (diphenylcyclopropenone) is used for moderate-to-severe or extensive alopecia areata. DPCP is a contact sensitiser applied to the scalp in progressively increasing concentrations, deliberately inducing a mild allergic contact dermatitis. This inflammatory signal redirects the immune response — shifting the T-lymphocyte population away from the follicle attack and allowing regrowth. It requires careful dose titration and monitoring but produces meaningful response rates in patients who have not responded adequately to corticosteroid treatment.
JAK Inhibitors: The New Treatment Landscape
JAK inhibitor therapy — including tofacitinib, ruxolitinib, and baricitinib — represents the most significant advance in alopecia areata treatment in decades. JAK inhibitors block the JAK-STAT signalling pathway through which T-lymphocytes are activated, directly suppressing the autoimmune attack on the follicle. Clinical trial data demonstrates impressive response rates in moderate-to-severe disease, including alopecia totalis and alopecia universalis. JAK inhibitor tofacitinib and baricitinib (FDA-approved for severe alopecia areata) are prescribed under dermatologist supervision with appropriate monitoring.
PRP as Adjunct Treatment
PRP hair (platelet-rich plasma) is used as an adjunct treatment in alopecia areata — providing growth factor support to the follicle bulb region and a mild immunomodulatory effect that complements primary immune-directed treatments. It is not a standalone treatment for alopecia areata but enhances outcomes when used alongside intralesional corticosteroids or topical immunotherapy, particularly in patients with partial response. See our PRP Hair page.
Treatment Comparison by Severity
| Disease Severity | First-Line Treatment | Adjunct / Second-Line |
|---|---|---|
| Patchy (limited) | Intralesional triamcinolone | PRP |
| Patchy (extensive) | Intralesional triamcinolone + Topical DPCP | PRP + Oral corticosteroids (short course) |
| Alopecia Totalis / Universalis | JAK inhibitor therapy | Topical immunotherapy DPCP |
| Rapidly expanding patches | Short course oral corticosteroids | Intralesional triamcinolone at stabilisation |
“In alopecia areata, the follicle is arrested — not gone. The earlier we intervene, the more follicles we reactivate before the immune attack establishes itself in the tissue.” — Dr. Rajat Kandhari
Prognosis: What Patients Should Understand
Approximately 50% of patients with limited patchy disease recover fully within one year, with or without treatment. Treatment accelerates and sustains this recovery. However, the condition can recur — the autoimmune predisposition persists, and new patches can appear even after successful treatment of previous ones.
Patients with extensive disease, alopecia totalis, alopecia universalis, nail pitting alopecia, onset in childhood, or a positive family history have a less favourable prognosis for complete sustained remission. For these patients, long-term management strategies — including JAK inhibitor therapy where appropriate — provide the most meaningful improvement in hair coverage and quality of life.
For an assessment and treatment plan, book a consultation at Dr. Rajat Kandhari’s clinic — S-79, Greater Kailash Part-1, South Delhi. Open Monday to Saturday, 9am to 8pm. Call or WhatsApp: +91 9315479193.
Frequently Asked Questions
Q1. Can alopecia areata be cured permanently?
Alopecia areata cannot be permanently cured in the sense of eliminating the autoimmune predisposition. However, many patients achieve sustained remission — particularly those with limited patchy disease. Even patients with severe disease can achieve significant regrowth with JAK inhibitor therapy, though maintenance treatment is often required.
Q2. What do exclamation mark hairs indicate?
Exclamation mark hairs found at the border of alopecia areata patches indicate active disease — follicles being damaged by the ongoing autoimmune attack. Their presence at a patch edge suggests the patch is still expanding and that treatment should begin promptly.
Q3. Is intralesional steroid injection painful?
There is some discomfort from the injections, similar to other dermal injections. A topical anaesthetic cream can be applied before the session to reduce discomfort. Most patients find the procedure manageable — and it remains the most effective first-line approach for patchy alopecia areata.
Q4. How is alopecia areata different from androgenetic hair loss?
Alopecia areata produces discrete patches in previously normal hair — the skin within the patch is smooth, follicles are intact but arrested. Androgenetic alopecia is a genetic, hormone-driven condition producing gradual diffuse thinning following a predictable pattern. Treatment approaches differ completely — androgenetic alopecia is managed with DHT blockers and growth stimulants; alopecia areata requires immune modulation.
Q5. At what age does alopecia areata typically start?
Alopecia areata most commonly presents before age 30 but can begin at any age. Childhood-onset disease is associated with a less favourable long-term prognosis than adult-onset. New patches can develop at any stage of life in susceptible individuals.
Q6. Where is the clinic located?
S-79, Greater Kailash Part-1, New Delhi 110048. Accessible from South Delhi including Hauz Khas, Defence Colony, Vasant Vihar, Lajpat Nagar. Monday to Saturday, 9am to 8pm. +91 9315479193.